A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part

Benzer Materyaller

• A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses
  Yazar:: Kallen, Karl-Josef, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• A novel, disruptive vaccination technology: Self-adjuvanted RNActive(®) vaccines
  Yazar:: Kallen, Karl-Josef, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy
  Yazar:: Hong, Henoch S., ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Self-adjuvanted RNActive(® )vaccines provide a promising platform for combination therapies with checkpoint inhibitors
  Yazar:: Kowalczyk, Aleksandra, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
  Yazar:: Sebastian, Martin, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)